Leaders don’t need more slides—they need more sensemaking. The future of presentations is clarity, story, and presence, not ...

NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational design. Interim ...

The most powerful internal events go beyond information sharing to create emotional connections among employees and between ...

The Trade & Policy Conference Track, taking place on Tuesday, October 21, is geared toward professionals involved in ...

Founded in 1998, SGC has earned its reputation as one of the most reliable grading companies in the hobby. Its iconic black ...

From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today ...

Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to ...

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient populationEncouraging safety and ...

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

The designs included elements like a new intercity bus station, a soaring, glass-walled addition to the Race Street front ...

The issuer is solely responsible for the content of this announcement.